volume 36, issue 3, P616-626 2010
DOI: 10.1038/npp.2010.193
View full text
Sign up to set email alerts

Abstract: Neurocognitive deficits are a core feature of schizophrenia and therefore represent potentially critical outcome variables for assessing antipsychotic treatment response. We performed genome-wide association studies (GWAS) with 492K single nucleotide polymorphisms (SNPs) in a sample of 738 patients with schizophrenia from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. Outcome variables consisted of a neurocognitive battery administered at multiple time points over an 18 month p…

Expand abstract